Over time, advances in the intracellular engineering of CAR T cells have improved the engineered T cells’ ability to produce more T cells after infusion into the patient and survive longer in the circulation, thus making the treatment more effective.
Mustang Bio brings significant expertise to the development of next generation CAR T cell therapy. We are rapidly advancing a number of promising candidates designed to hit unique targets with first in class potential for both hematologic and solid tumor cancers.
To view an overview of our programs, visit our Pipeline page.